5 results about "Obstructive azoospermia" patented technology

This invention provides a biomarker for spermatogenesis disorders and its application, wherein the biomarker is the MNDA molecule. This application characterizes the functional abnormalities or spermatogenesis disorders of Sertoli cells by detecting the expression level of MNDA molecules on cells in testicular tissue sections, and can therefore be used for the clinical diagnosis of non-obstructive azoospermia.

The invention discloses a method for distinguishing obstructive azoospermia and non-obstructive azoospermia based on ultrasonic images and machine learning, and relates to the technical field of image analysis and machine learning, all patients are subjected to bilateral scrotum ultrasonic examination before operation; patients are divided into a training set, a validation set, and a test set according to the use of the dataset. In the training set, image omics features are extracted from the left testis ultrasonic image and the right testis ultrasonic image, and key features related to obstructive azoospermia are screened out; on the basis of the selected radiomics features, five machine learning models are constructed, including a k-nearest neighbor model, a logistic regression model, a multi-layer perceptron model, a random forest model and a support vector machine model; analyzing and evaluating the diagnostic performance and clinical application value of the model in the three groups of data through an ROC curve and a clinical decision curve; and explaining the final machine learning model by using SHAP analysis. The method has important value in distinguishing obstructive azoospermia and non-obstructive azoospermia, wherein the logistic regression model shows better diagnostic performance compared with other four models.

The invention provides a product related to non-obstructive azoospermia microscopic sperm extraction, application and a method. The invention discloses application of a reagent for detecting clinical information in preparation of a non-obstructive azoospermia microscopic sperm extraction product. The clinical information comprises age, testis size, testosterone, estradiol E2, androgen T, follicle stimulating hormone FSH, statin B and seminal plasma cell-free DNA motif diversity score. The prediction method comprises the following steps: acquiring clinical information of a to-be-tested object; inputting the clinical information into a prediction model based on machine learning to obtain a probability P of successful microscopic sperm extraction; and according to comparison between the probability P and a reference value, diagnosing or predicting whether the to-be-detected object is suitable for microscopic sperm collection. The prediction method provided by the invention can be used for improving the accuracy of predicting the success rate of microscopic sperm extraction of non-obstructive azoospermia, and has a relatively good clinical application value.

The present application relates to the application of RNF20 gene in the preparation of therapeutic drugs for azoospermia caused by RNF20 gene mutation, and the therapeutic drugs. The present application rescues the non-obstructive azoospermia of the young mouse with RNF20 gene deletion by introducing the RNF20 gene expression vector into the testicular tissue of the mouse through microinjection and electrotransformation. Further, the non-obstructive azoospermia of the adult mouse with RNF20 gene deletion is rescued by adding an autophagy inhibitor in the microinjection.

The invention provides a dyszoospermia biomarker and an application thereof. The biomarker is an MNDA molecule. According to the application, the state of dysfunction or dyszoospermia of Sertoli cells is represented by detecting the expression level of MNDA molecules on cells in a testicular tissue slice, so that the application can be used for clinical diagnosis and the like of non-obstructive azoospermia.